Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FirST biologic strategies in ulcerative colitis
2024-514964-24-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vedolizumab, infliximab, filgotinib and ustekinumab CT-P43 in autoimmune colitis (4 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Composite remission between week 4 and week 52. Planned start Apr 2026; status: authorised.
02
Drugs
vedolizumabinfliximabfilgotinibustekinumab CT-P43
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-514964-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514964-24-00.